Want to join the conversation?
$MRK said that the U.S. FDA accepted for review the Biologics License Application (BLA) for bezlotoxumab, which is used for the prevention of Clostridium difficile (C. difficile) infection recurrence. The FDA granted Priority Review for bezlotoxumab, with a Prescription Drug User Fee Act (PDUFA) action date of July 23, 2016.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.